В тези проучвания 11, 9% от пациентите на Trudexa и 8, 1% от тези на плацебо и р
In these trials, 11.9% of patients treated with Trudexa and 8.1% of placebo and active control− treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at week 24.